Crescendo Biologics Limited

Crescendo Biologics Limited

Crescendo Biologics is a Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.

Telephone: +44 (0)1223 497 140
Address: Meditrina 260, Babraham Research Campus, Babraham
Postcode: CB22 3AT
Country: United Kingdom
Membership type:Corporate 21-50 (£500+VAT pa)

Next Generation Antibody Therapeutics

The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

Crescendo brings together two technologies invented by scientists at the Babraham Institute in Cambridge: a novel transgenic technology for in vivo generation of human heavy chain antibodies (and thereby VH fragments), and a ribosome display platform for affinity optimisation in vitro. These are being developed to generate a combined platform for discovery and optimisation of human VH-based therapeutics that addresses key issues with existing in vitro or non-human in vivo platforms.

For more information, see

Zai Lab and Crescendo Biologics enter exclusive worldwide licence agreement

Zai Lab Limited, a Shanghai-based innovative biopharmaceutical company, and Cambridge-based Crescendo Biologics Ltd, the developer of multi-functional biologics, announced today an exclusive, worldwide licensing agreement under which Zai Lab will develop, commercialise, and manufacture a topical, innovative antibody VH domain therapeutic for potential application in inflammatory indications.

30 May 2018Read in full

Crescendo Biologics raises $70 million in Series B financing

Crescendo Biologics Ltd, the developer of multi-functional biologics with a focus on novel targeted T-cell engagers, announced that it has completed a $70 million (€57 million) Series B financing. This is the largest disclosed Series B biotech financing in Europe this year.

1 May 2018Read in full

Crescendo Biologics and Takeda enter collaboration for Humabody®-based therapeutics

A new collaboration between Crescendo Biologics and Takeda aims to generate tumor targeting drug conjugates and immuno-oncology therapeutics.

10 October 2016Read in full

Crescendo Biologics launches new strategy in oncology drug discovery & development

Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics, has announced the launch of the Company’s new drug development strategy.

15 October 2015Read in full

Crescendo Biologics wins Innovate UK Funding Award

Crescendo Biologics expands ADC Programmes with Innovate UK Funding award: Biomedical Catalyst Award to support development of new therapies to target prostate cancer

27 May 2015Read in full

Crescendo Biologics article appears in 'Nature' Publication

Nature Biopharma Dealmakers: Humabody Fragments™: small and perfectly formed

9 March 2015Read in full

Crescendo Biologics receives further investment from Astellas Venture Management

Crescendo Biologics’ receives further investment from Astellas Venture Management to develop novel Humabody™ Therapeutics targeting immune checkpoint inhibitors.

14 December 2014Read in full

Crescendo Biologics: OBN Award

Crescendo Biologics recognised at OBN Annual Awards Dinner

3 September 2014Read in full

EMBL Ventures invests in Crescendo Biologics

EMBL Ventures invests £2M ($3.3M) in a second close of Crescendo Biologics’ Series A Financing

3 April 2014Read in full

Crescendo Biologics wins Cambridge Business Innovation Award

Crescendo Biologics Limited today announces it has been awarded the prize for Business Innovation at the Cambridge News Business Excellence Awards 2014.

28 March 2014Read in full

  1. 1
  2. 2